VYNE — VYNE Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1566044 ·
Last close
$27.85
Market Cap
$18.60M
52W High
$46.95
52W Low
$0.61
ADV30
950,711
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 86,000 | — | -3,816,000 | -3,585,000 | 25,873,000 | 24,631,000 | 1,236,000 |
| Dec 2025 | 130,000 | — | -5,219,000 | -4,837,000 | 30,160,000 | 24,027,000 | 2,395,000 |
| Sep 2025 | 169,000 | — | -7,792,000 | -7,280,000 | 36,132,000 | 19,346,000 | 4,044,000 |
| Jun 2025 | 69,000 | — | -7,542,000 | -5,755,000 | 44,718,000 | 22,047,000 | 5,836,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,744,000
Investing CF
$22,237,000
Financing CF
$-71,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.58
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-761,238,000
Inventory
—
Receivables
—
ST Investments
$297,000
EBIT TTM
$-24,369,000
Pretax Income TTM
$-21,714,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$454,000
EBITDA
$-24,345,000
Free Cash Flow
$-20,400,000
Enterprise Value
$-5,876,852
Total Cash
$24,928,000
Total Debt
$0
Shares Out
667,701
Trailing EPS
$-27.58
Book Value
$36.93
ROE
-63.2%
ROA
-37.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 570,000 | -29,749,000 | -26,483,000 | 30,160,000 | 2,395,000 | — | -33,124,000 |
| Dec 2024 | 501,000 | -43,637,000 | -39,834,000 | 66,905,000 | 14,819,000 | — | -33,972,000 |
| Dec 2023 | 424,000 | -29,258,000 | -28,452,000 | 97,685,000 | 8,950,000 | — | -25,341,000 |
| Dec 2022 | 477,000 | -34,295,000 | -23,210,000 | 40,758,000 | 9,556,000 | — | -29,200,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$3,269,000
NetIncome TTM
$47,875,000
OpCashFlow TTM
$0
Assets (Latest)
$93,742,000
Forward EPS
$-82.50
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QNTM | Quantum Biopharma Ltd. | $18.49M | $2.89 | — |
| NCEL | NewcelX Ltd. | $18.79M | $3.49 | — |
| CELU | Celularity Inc | $18.39M | $0.64 | — |
| MRKR | Marker Therapeutics, Inc. | $18.84M | $1.13 | — |
| DARE | Dare Bioscience, Inc. | $18.27M | $1.22 | — |
News headlines (Yahoo Finance, 1h cache)
Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101
2026-07-27 13:17 · Yahoo
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye D
2026-07-27 11:00 · Yahoo
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
2026-07-23 20:26 · Yahoo
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
2026-07-21 12:00 · Yahoo
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
2026-07-10 12:00 · Yahoo
BC-Most Active Stocks
2025-12-17 15:30 · Yahoo
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
2025-12-17 13:00 · Yahoo
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
2025-11-06 14:15 · Yahoo
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
2025-11-06 13:00 · Yahoo
VYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
2025-08-18 18:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.